|Articles|April 11, 2022
- Pharmaceutical Executive-04-01-2022
- Volume 42
- Issue 4
Pharmaceutical Executive, April 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive April 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 4 years ago
Seven Lessons I Learned Working at a Biotech Startupalmost 4 years ago
Next-Gen Partnerships: The Ascent of Advanced Therapiesalmost 4 years ago
Advantage Pharma: Capitalizing on Workforce Lessonsalmost 4 years ago
Diversity in Action: Q&A With Reshma Kewalramanialmost 4 years ago
Diversity in Action: Q&A With Bob McMahonalmost 4 years ago
Women and Diversity in Industry C-Suites: New Scorecards Tell the Storyalmost 4 years ago
A Dogged Devotionalmost 4 years ago
Surviving Biotech’s Longest and Steepest Bear Market Everalmost 4 years ago
The Case for Elevating a Brand’s Price Propositionalmost 4 years ago
The Impact of Hybrid Workplace Decisions On DE&I DynamicsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Your Phase III Clinical Protocol Is Your Initial Product Launch
2
Pharmaceutical Executive Daily: Public Citizen Sues The Trump Administration Over Undisclosed Drug Price Agreements
3
AstraZeneca Enters $4.7 Billion Collaboration Agreement with CSPC Pharmaceuticals
4
Taking Advantage of ‘Hidden Gem’ Talent Hubs
5

